SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-121812
Filing Date
2022-11-23
Accepted
2022-11-23 17:11:24
Documents
12
Period of Report
2022-11-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2231220d1_8k.htm   iXBRL 8-K 21821
  Complete submission text file 0001104659-22-121812.txt   196989

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20221118.xsd EX-101.SCH 3322
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20221118_lab.xml EX-101.LAB 34986
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20221118_pre.xml EX-101.PRE 22617
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2231220d1_8k_htm.xml XML 3695
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 221417054
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences